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Abstract
Background: Spontaneous rupture is rare complication of hepatocellular carcinoma (HCC) with
high mortality rate in cirrhotic cases. The aim of this study was to determine the factors influencing
prognosis in cases of spontaneously ruptured HCC and to investigate the outcomes of the
treatments employed, especially transcatheter arterial embolization (TAE).
Methods:  A retrospective multicenter study was conducted in 48 cirrhotic patients with
spontaneous rupture of HCC. Conservative treatment was employed in 32 patients (ConT group)
and TAE was performed in 16 patients (TAE group).
Results: The median survival time (MST) in the ConT group was only 13.1 days and the survival
rate was extremely poor: 59.4% at 7 days, 37.5% at 14 days, and 6.3% at 30 days. On the other
hand, the MST in the TAE group was 244.8 days and the survival rate was 87.5% at 1 month, 56.3%
at 3 months, 23.4% at 12 months, and 15.6% at 24 months. According to the results of univariate
analyses, factors associated with poor hepatic function and poor suitability for TAE was important
determinants of short-term death (less than 3 weeks) among the patients (p < 0.05). On the other
hand, among the patients in whom initial TAE was successfully performed (n = 15), a multivariate
analysis showed that a maximum tumor size not exceeding 7 cm was the only independent factor
determining long-term survival (p = 0.0130).
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Conclusion: Despite the inherent limitations of this retrospective study, TAE appears to be a
useful treatment strategy for cirrhotic patients with spontaneous HCC rupture, as it yielded a
longer survival period compared with conservative treatment in patients with ruptured HCC.
Among the patients with ruptured HCC in whom initial TAE was successfully performed, the
maximum tumor size was an important factor influencing survival.
Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon neoplasms encountered, and its incidence is increas-
ing worldwide because of the increasing prevalence of
hepatitis C virus infections [1-5]. One of the life-threaten-
ing complications of HCC is the spontaneous rupture of
the tumor, with intra-peritoneal hemorrhage. Spontane-
ous rupture of HCC occurs in 3 to 15% of all patients with
HCC, and high mortality rates in the range of 32 to 100%
have been reported [6-15]. The following treatments have
been employed for the treatment of ruptured HCC: emer-
gent hepatic resection, placation or packing, hepatic artery
ligation, and transcatheter arterial embolization (TAE) [9-
18]. However, patients with advanced HCC tend to have
poor hepatic function as a result of chronic hepatitis or
liver cirrhosis. Therefore, a better understanding of the
disease, wider recognition of this potential complication,
improved methods of assessing liver function preopera-
tively, and less invasive methods of hemostasis may con-
tribute to improved survival in cases of ruptured HCC.
The aim of this study was to determine the factors associ-
ated with prognosis in cases of spontaneously ruptured
HCC and to investigate the outcomes of treatment, espe-
cially transcatheter arterial embolization (TAE).
Methods
From January 1995 to May 2008, a total of 48 cirrhotic
patients with spontaneously ruptured HCC were admitted
to the Yokohama City University Hospital (33 patients),
the Hiratsuka City Hospital (10 patients), and the Mach-
ida Municipal Hospital (5 patients).
The diagnosis of HCC was made based on the identifica-
tion of a space-occupying lesion(s) in the liver using com-
puted tomography (CT) or ultrasonography (US). The
presence of hemoperitoneum in the patients was diag-
nosed by the demonstration of bloody fluid in the perito-
neum by an abdominal puncture. Spontaneous rupture
was the initial symptom of HCC in 4 patients, while in the
remaining 44 patients, the spontaneous rupture of HCC
was diagnosed during the follow-up period for liver cir-
rhosis (LC) or HCC.
The past medical history, vital signs, blood counts, blood
chemistry, coagulation test results, levels of tumor mark-
ers, progression profile of HCC (number of tumors, max-
imum tumor size, presence of portal vein tumor
thrombosis and presence of extra-hepatic metastasis),
treatments employed, and survival rates were recorded.
Shock at the time of admission was defined as a systolic
blood pressure of < 80 mmHg and pulse rate of > 100
b.p.m. The LC status was evaluated using the Child-Pugh
criteria using a combination of clinical (presence of
hepatic encephalopathy, ascites) and laboratory data
(serum bilirubin levels, prothrombin time (PT) and
serum albumin levels). Staging of the HCC was performed
according to the TNM staging system proposed by the
Liver Cancer Study Group of Japan [19]: stage I (fulfill-
ment of three intra-hepatic conditions: solitary, no more
than 2 cm, no vessel invasion), stage II (fulfillment of two
out of three intra-hepatic conditions), stage III (fulfill-
ment of one of three intra-hepatic conditions), stage IVA
(fulfillment of none of the three intra-hepatic conditions
with no distant metastases, or any intra-hepatic condition
with lymph node metastases), and stage IVB (any intra-
hepatic condition with distant metastases). Patients were
not included if they fulfilled one or more of the following
criteria: presence of poorly controlled hepatic encepha-
lopathy; presence of poorly controlled ascites; presence of
jaundice (or a serum total bilirubin level higher than 5.0
mg/dL); or a poor performance status. An attempt was
made to obtain informed consent for performing emer-
gent TAE from all the patients, and the decision to per-
form TAE was made according to each patient's wishes.
Emergent TAE was performed for hemostasis or the pre-
vention of re-bleeding in 16 patients who provided their
informed consent (TAE group, n = 16), while conservative
treatment was employed in the remaining 32 patients
(ConT group, n = 32). The patient characteristics in each
group are shown in Table 1. This study was approved by
the Ethics Committee of Yokohama City University
School of Medicine.
Statistical analysis
The statistical analysis was conducted using StatView ver-
sion 5.0 software (SAS, Cary, NC). Group comparisons
were performed using the chi-square test for independ-
ence or the Fisher exact test for comparisons of the two
groups. The overall survival rate in each group was deter-
mined using the Kaplan-Meier method and a log-rank
test, whit the survival period defined as the length of time
from the onset of the spontaneous rupture of the HCC
until the death of the patient. A multivariate analysis wasBMC Gastroenterology 2009, 9:29 http://www.biomedcentral.com/1471-230X/9/29
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Table 1: Comparison of patient characteristics between ConT and TAE groups
Total ConT group TAE group p – value
Patients (n) 48 32 16
Age 69.3 ± 8.1 70.2 ± 8.7 67.5 ± 6.6 NS
Sex (n, %)
Male 36 (75%) 22 (69%) 14 (87%) NS
Female 12 (25%) 10 (31%) 2 (13%)
Etiology of LC (n, %)
HCV 32 (67%) 21 (65%) 11 (69%)
HBV 4 (8%) 3 (9%) 1 (6%) NS
Alcohol 5 (10%) 4 (13%) 1 (6%)
NonB-nonC 7 (15%) 4 (13%) 3 (19%)
Past history of HCC treatment (n, %)
presence 36 (75%) 24 (75%) 12 (75%) NS
absence 12 (25%) 8 (25%) 4 (25%)
Admission duration for the treatment of HCC 3.0 ± 2.8 3.2 ± 2.9 2.6 ± 2.7 NS
Months from first treatment of HCC 31.0 ± 32.7 35.2 ± 36.4 22.8 ± 22.3 NS
Shock (n, %)
presence 22 (48%) 16 (50%) 6 (38%) NS
absence 26 (52%) 16 (50%) 10 (62%)
Albumin (g/dL) 3.2 ± 0.4 3.1 ± 0.5 3.3 ± 0.3 NS
Total bilirubin (mg/dL) 1.8 ± 0.9 1.9 ± 0.9 1.5 ± 0.7 NS
PT (INR) 1.25 ± 0.13 1.24 ± 0.12 1.29 ± 0.16 NS
ICG at 15 min 33.1 ± 13.2 32.9 ± 12.9 33.5 ± 14.2 NS
AFP (ng/mL) 59163 84009 9472 NS
PIVKA-II (mAU/mL) 39589 55199 8370 NS
Ascites (n, %)
presence 32 (67%) 23 (72%) 9 (56%) NS
absence 16 (33%) 9 (28%) 7 (44%)
Hepatic encephalopathy (n, %)
presence 25 (52%) 17 (53%) 8 (50%) NS
absence 23 (48%) 15 (47%) 8 (50%)
AST (IU/L) 91 ± 73 94 ± 79 76 ± 51 NS
ALT (IU/L) 53 ± 35 52 ± 35 53 ± 35 NS
Hemoglobin (g/dL) 11.5 ± 1.9 11.1 ± 1.9 12.2 ± 1.8 NS
Platelet count (× 104) 14.9 ± 7.8 14.1 ± 6.0 16.6 ± 10.5 NS
Creatinine (mg/dL) 1.03 ± 0.66 1.08 ± 0.75 0.92 ± 0.42 NS
Child-Pugh classification (n, %)
A 12 (24%) 7 (22%) 5 (31%)
B 18 (38%) 11 (34%) 7 (44%) NS
C 18 (38%) 14 (44%) 4 (25%)
Child-Pugh score 8.0 ± 2.1 8.2 ± 2.1 7.8 ± 1.9 NS
Number of tumors (n, %)
single 6 (13%) 2 (6%) 4 (25%) NS
multiple 42 (87%) 30 (94%) 12 (75%)
Maximum tumor size (cm) 7.0 ± 2.0 7.1 ± 3.9 6.9 ± 2.8 NS
Maximum tumor size (n, %)
≤ 7 cm 23 (48%) 15 (47%) 8 (50%) NS
> 7 cm 25 (52%) 17 (53%) 8 (50%)
Portal vein tumor thrombosis
presence 24 (50%) 16 (50%) 8 (50%) NS
absence 24 (50%) 16 (50%) 8 (50%)
Clinical stage
II 1 (4%) 0 (0%) 1 (6%)
III 22 (44%) 12 (38%) 10 (63%) NS
IVA 15 (31%) 11 (34%) 4 (25%)
IVB 10 (21%) 9 (28%) 1 (6%)
Abbreviations: ConT, conservative treatment: TAE, transcatheter arterial embolization: LC, liver cirrhosis: HCV, hepatitis C virus: HBV, hepatitis B 
virus: HCC, hepatocellular carcinoma: PT (INR), prothrombin time (international ratio): ICG, indocyanine green: AFP, alpha-fetoprotein: PIVKA-II, 
protein induced vitamin K absence-II: AST, aspartate aminotransferase: ALT, alanine aminotransferase: NS, not significant.BMC Gastroenterology 2009, 9:29 http://www.biomedcentral.com/1471-230X/9/29
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Table 2: Univariate analysis of factors influencing overall 21-day survival (n = 48).
50% Survival time: 21 days Patients who died within 21 days Patients who survived longer than 21 days p – value
Patients (n) 24 24
Age 70.8 ± 8.2 67.8 ± 7.9 NS
Sex (n, %)
Male 19 (79%) 17 (71%) NS
Female 5 (21%) 7 (29%)
Etiology of LC (n, %)
HCV 16 (67%) 16 (67%)
HBV 3 (13%) 1 (4%) NS
Alcohol 3 (13%) 2 (7%)
NonB-nonC 2 (7%) 5 (22%)
Past history of HCC treatment (n, %)
presence 19 (79%) 17 (71%) NS
absence 5 (21%) 7 (29%)
Admission duration for the treatment of HCC 3.4 ± 3.0 2.6 ± 2.7 NS
Months from first treatment of HCC 31.6 ± 28.0 30.5 ± 37.4 NS
Shock (n, %)
presence 15 (62%) 7 (29%) p = 0.0205
absence 9 (38%) 17 (71%)
Albumin (g/dL) 3.0 ± 0.4 3.4 ± 0.4 p = 0.0008
Total bilirubin (mg/dL) 2.2 ± 1.0 1.5 ± 0.6 p = 0.0052
PT (INR) 1.24 ± 0.12 1.27 ± 0.15 NS
ICG at 15 min 35.6 ± 12.1 30.6 ± 14.0 NS
AFP (ng/mL) 92400 25926 NS
PIVKA-II (mAU/mL) 35513 43666 NS
Ascites (n, %)
presence 12 (50%) 13 (54%) NS
absence 12 (50%) 11 (46%)
Hepatic encephalopathy (n, %)
presence 16 (67%) 9 (38%) p = 0.0431
absence 8 (33%) 15 (62%)
AST (IU/L) 127 ± 86 76 ± 45 p = 0.0142
ALT (IU/L) 61 ± 42 44 ± 23 NS
Hemoglobin (g/dL) 11.1 ± 2.1 11.8 ± 1.7 NS
Platelet count (× 104) 12.9 ± 5.5 16.9 ± 9.2 NS
Creatinine (mg/dL) 0.99 ± 0.40 1.06 ± 0.85 NS
Child-Pugh classification (n, %)
A 2 (8%) 10 (42%)
B 10 (42%) 8 (33%) p = 0.0229
C 12 (50%) 6 (25%)
Child-Pugh score 9.2 ± 1.8 7.6 ± 2.0 p = 0.0074
Number of tumors (n, %)
single 1 (4%) 5 (21%) NS
multiple 23 (96%) 19 (79%)
Maximum tumor size (cm) 7.2 ± 3.5 7.7 ± 3.5 NS
Maximum tumor size (n, %)
≤ 7 cm 13 (54%) 9 (38%) NS
> 7 cm 11 (46%) 15 (62%)
Portal vein tumor thrombosis
presence 12 (50%) 12 (50%) NS
absence 12 (50%) 12 (50%)
Clinical stage
II 0 (0%) 1 (4%)
III 11 (46%) 11 (46%) NS
IVA 8 (33%) 7 (29%)
IVB 5 (21%) 5 (21%)
Performing TAE
Performed 1 (4%) 15 (62%) p < 0.0001
Not performed 23 (96%) 9 (38%)
Abbreviations: LC, liver cirrhosis: HCV, hepatitis C virus: HBV, hepatitis B virus: HCC, hepatocellular carcinoma: PT (INR), prothrombin time (international 
ratio): ICG, indocyanine green: AFP, alpha-fetoprotein: PIVKA-II, protein induced vitamin K absence-II: AST, aspartate aminotransferase: ALT, alanine 
aminotransferase: TAE, transcatheter arterial embolization: NS, not significant.BMC Gastroenterology 2009, 9:29 http://www.biomedcentral.com/1471-230X/9/29
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performed using the Cox hazard regression model. The
cut-off level for each parameter was decided based on the
median level for all the patients. P values < 0.05 were con-
sidered statistically significant. The closing date for the
study was May 31, 2008.
Results
The initial symptoms of spontaneous rupture of HCC
were the sudden onset of abdominal pain (28 patients,
58%), shock at admission (22 patients, 46%), and
abdominal distension (20 patients, 42%). With regard to
the stage of LC, 12 patients were classified as Child-Pugh
A (24%), 18 as Child-Pugh B (38%), and 18 as Child-
Pugh C (38%). As for the stage of HCC, one patient was
classified as clinical stage II (2%), 22 patients as stage III
(46%), 15 as stage IVA (31%), and 10 as stage IVB (21%).
The HCC was located on the liver surface in all the
patients. Most of the patients had advanced HCC, and 42
patients had multiple HCCs (88%); among these patients,
25 patients had a maximum tumor size of > 7 cm (52%),
and 24 patients had portal vein tumor thrombosis (50%)
(Table 1). Univariate analyses identified shock at admis-
sion (p = 0.0205), the presence of hepatic encephalopathy
(p = 0.0431), a high Child-Pugh score (p = 0.0074), a high
serum bilirubin level (p = 0.0052), a high serum aspartate
transferase (AST) level (p = 0.0142), a low serum albumin
level (p  = 0.0008), and non-suitability for TAE (p  <
0.0001) as determinants of a poor 21-day (50% survival
time of all the patients) survival (Table 2). A multivariate
analysis using the Cox hazard regression model (includ-
ing all the patients; n = 48) identified TAE as the only
independent factor determining a relatively long survival
period (p < 0.0001) (Table 3).
TAE was performed in 16 patients. The extravasation of
the blood from the ruptured HCC was revealed by digital
subtraction angiography (DSA) in 9 patients (56%). TAE
was successful in controlling acute hemorrhage in 15
patients (success rate, 94%). The MST in the TAE group
was significantly better than that in the ConT group
(244.8 days [range, 1–1200 days] vs. 13.1 days [range, 1–
35 days], p = 0.0003). The cumulative survival rates in the
ConT group were 59.4% at 7 days, 37.5% at 14 days, and
6.3% at 30 days. The cumulative survival rates in the TAE
group were significantly superior to those in the ConT
group, namely, 87.5% at 1 month, 56.3% at 3 months,
31.3% at 6 months, 23.4% at 12 months, and 15.6% at 24
months (p < 0.0001) (Figure 1).
In a further analysis of the patients in whom the initial
TAE was successfully performed (n  = 15), a univariate
analysis identified a maximum tumor size exceeding 7 cm
(p = 0.0052) as a significant determinant of a poor 140-
day (median survival time of this group) survival, while
the presence of portal vein tumor thrombosis (p = 0.0572)
exhibited a tendency toward being a determinant factor
(Table 4). A multivariate analysis identified only a maxi-
mum tumor size exceeding 7 cm (p  = 0.0135) as an
inverse independent factor determining relatively long-
term survival (Table 5).
Among the patients in whom initial TAE was successfully
performed, the MST among the patients in whom the
maximum tumor size was ≤ 7 cm (n = 6) was significantly
better than that among the patients in whom the maxi-
Cumulative survival rates in the ConT (conservative treat- ment) group and in the TAE (transcatheter arterial emboliza- tion) group Figure 1
Cumulative survival rates in the ConT (conservative 
treatment) group and in the TAE (transcatheter 
arterial embolization) group.
Table 3: Multivariate analysis of factors influencing overall survival (n = 48).
Factor Odds Ratio 95% C.I. p – value
Shock: presence 1.522 0.788 – 2.941 NS
Albumin > 3.2 g/dL 0.979 0.408 – 2.350 NS
Total bilirubin > 2.0 mg/dL 1.046 0.623 – 1.754 NS
Hepatic encephalopathy: presence 1.094 0.513 – 2.331 NS
AST > 90 IU/L 1.035 0.472 – 2.270 NS
Child-Pugh: C 1.858 0.686 – 5.031 NS
TAE performed 0.032 0.006 – 0.163 p < 0.0001
Abbreviations: AST, aspartate aminotransferase: TAE, transcatheter arterial embolization: NS, not significant.BMC Gastroenterology 2009, 9:29 http://www.biomedcentral.com/1471-230X/9/29
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Table 4: Univariate analysis of factors influencing 140-day survival among patients in whom initial TAE was successfully performed (n = 15).
50% Survival time: 140 days Patients who died within 140 days Patients who survived longer than 140 days p – value
Patients (n) 9 6
Age (years) 67.1 ± 6.1 68.8 ± 8.2 NS
Sex (n, %)
Male 8 (89%) 5 (83%) NS
Female 1 (11%) 1 (17%)
Etiology of LC (n, %)
HCV 5 (56%) 5 (83%)
HBV 1 (11%) 0 (0%) NS
Alcohol 1 (11%) 0 (0%)
NonB-NonC 2 (22%) 1 (17%)
Past history of HCC treatment (n, %)
presence 8 (89%) 4 (67%) NS
absence 1 (11%) 2 (33%)
Admission duration for treatment of HCC 3.6 ± 3.1 1.7 ± 1.6 NS
Months from first treatment of HCC 22.6 ± 21.9 27.0 ± 24.6 NS
Shock (n, %)
presence 3 (33%) 3 (50%) NS
absence 6 (67%) 3 (50%)
Albumin (g/dL) 3.3 ± 0.4 3.4 ± 0.3 NS
Total bilirubin (mg/dL) 1.5 ± 0.7 1.6 ± 0.6 NS
PT (INR) 1.30 ± 0.19 1.29 ± 0.15 NS
ICG at 15 min (%) 35.1 ± 17.1 32.0 ± 11.0 NS
AFP (ng/ml) 1686 250 NS
PIVKA-II (mAU/mL) 7186 7758 NS
Ascites (n, %)
presence 5 (56%) 4 (67%) NS
absence 4 (44%) 2 (33%)
Hepatic encephalopathy (n, %)
presence 4 (44%) 4 (67%) NS
absence 5 (56%) 2 (33%)
AST (IU/L) 86 ± 59 66 ± 41 NS
ALT (IU/L) 58 ± 39 46 ± 33 NS
Hemoglobin (g/dL) 12.7 ± 1.4 11.7 ± 2.4 NS
Platelet count (× 104) 16.7 ± 12.3 16.4 ± 9.5 NS
Creatinine (mg/dL) 0.80 ± 0.14 0.86 ± 0.16 NS
Child-Pugh classification (n, %)
A 3 (33%) 2 (33%)
B 4 (45%) 2 (33%) NS
C 2 (22%) 2 (33%)
Child-Pugh score 7.7 ± 2.0 8.0 ± 2.1 NS
Number of tumors (n, %)
single 2 (22%) 1 (17%) NS
multiple 7 (78%) 5 (83%)
Maximum tumor size (cm) 7.4 ± 1.7 6.3 ± 3.3 NS (p = 0.1221)
Maximum tumor size (n, %)
≤ 7 cm 1 (11%) 5 (83%) p = 0.0052
> 7 cm 8 (89%) 1 (17%)
Portal vein tumor thrombosis
presence 6 (67%) 1 (17%) NS (p = 0.0572)
absence 3 (33%) 5 (83%)
Clinical stage
II, III 5 (56%) 5 (83%) NS
IVA, IVB 4 (44%) 1 (17%)
Abbreviations: TAE, transcatheter arterial embolization: LC, liver cirrhosis: HCV, hepatitis C virus: HBV, hepatitis B virus: HCC, hepatocellular 
carcinoma: PT (INR), prothrombin time (international ratio): ICG, indocyanine green: AFP, alpha-fetoprotein: PIVKA-II, protein induced vitamin K 
absence-II: AST, aspartate aminotransferase: ALT, alanine aminotransferase: NS, not significant.BMC Gastroenterology 2009, 9:29 http://www.biomedcentral.com/1471-230X/9/29
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mum tumor size was > 7 cm (n = 9) (523.3 days [range,
60–1200 days] vs. 82.1 days [range, 1–150 days], p  =
0.0080). Furthermore, the cumulative survival rate among
the patients in whom the maximum tumor size was ≤ 7
cm was significantly better than that among the patients
in whom the maximum tumor size was > 7 cm (100%,
83.3%, 83.3% and 50.0% vs. 77.8%, 44.4%, 0% and 0%
at 1 month, 3 months, 6 months and 12 months, respec-
tively; p = 0.0030) (Figure 2).
All the patients in the ConT group died within 35 days of
hospitalization during the first hospital admission. In the
ConT group, the main cause of death was re-rupture or re-
bleeding of HCC (23 patients; 72%). On the other hand,
in the TAE group, 9 patients (60%) were discharged from
the hospital. Fifteen patients in the TAE group died during
the follow-up period of this study. The main cause of
death in the TAE group was hepatic failure (10 patients,
67%). Only two patients (13%) died of re-rupture or re-
bleeding of HCC (Table 6).
Discussion
Spontaneous rupture of HCC is a fatal complication of
advanced HCC. While previous studies have shown a very
poor prognosis, with a 30-day mortality rate in the range
of 30 – 70% [10-15,20,21], recent reports have indicated
a significant decrease in the mortality rate. In our study,
we observed an overall 30-day mortality rate of 67%,
while the mortality rate was only 6.7% (one patient)
among the patients in whom initial TAE treatment was
successful (15 patients).
Univariate analyses identified various factors, including
the presence of hepatic encephalopathy, a high Child-
Pugh score, a high serum bilirubin level, a high serum AST
level, and a low serum albumin level (all of which are
associated with poor liver function) as significantly influ-
encing the short-term death rate (within 3 weeks) among
the cases with ruptured HCC. In contrast, factors associ-
ated with the progression of HCC, such as the number of
tumors, the maximum tumor size, and portal vein tumor
thrombosis, were not revealed by univariate analyses to be
significant factors influencing the short-term death rate in
patients with ruptured HCC. A multivariate analysis
including all the patients (n = 48) identified the perform-
ance of TAE as the only independent factor influencing
survival. Regardless of the status of HCC progression, re-
rupture or re-bleeding of HCC as well as short-term death
could be prevented among patients in whom initial TAE
was successfully performed. These results suggest that TAE
is a useful treatment strategy for the spontaneous rupture
of HCC and that factors reflecting the background liver
function are important factors influencing short-term
mortality.
Hepatic resection is one of the best treatment options for
ruptured HCC, but it is technically difficult to perform in
cirrhotic liver and its success depends on the severity of
the cirrhosis. One group reported that only 12.5% of
patients with ruptured HCC could be managed with
hepatic resection, while another group reported a percent-
age of 59.3%. A similar situation was noted in relation to
TAE treatment. Some groups reported the presence of
shock at admission as an important factor influencing the
survival time [14,16,20-22]. Shock in patients with the
spontaneous rupture of HCC is caused by hypovolemia
resulting from hemorrhage. In addition, patients with LC
or liver failure have underlying coagulopathy. Therefore,
emergent TAE is difficult to perform in patients with
shock. In our study, a univariate analysis in the ConT
group also identified shock at admission as an independ-
ent factor influencing the short-term death rate. Another
group also reported that a serum total bilirubin level of
higher than 2.92 mg/dL (50 μmol/L) was a critical predic-
Cumulative survival rates in patients according to maximum  tumor size Figure 2
Cumulative survival rates in patients according to 
maximum tumor size. Abbreviations: TAE, transcatheter 
arterial embolization: HCC, hepatocellular carcinoma.
Table 5: Multivariate analysis of factors influencing the survival of patients in whom initial TAE was successfully performed (n = 15).
Factor Odds Ratio 95% C.I. p – value
Maximum tumor size > 7 cm 26.304 1.966 – 352.005 p = 0.0135
Portal vein tumor thrombosis: absence 0.444 0.080 – 2.475 NS (p = 0.3545)
Abbreviations: TAE, transcatheter arterial embolization: NS, not significant.BMC Gastroenterology 2009, 9:29 http://www.biomedcentral.com/1471-230X/9/29
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tor of survival. In a series of patients treated with TAE and
reported by Ngan et al. [23], none of the patients with a
serum total bilirubin level higher than 2.92 mg/dL (50
μmol/L) survived longer than 9 weeks (median survival, 1
week), while patients with a serum total bilirubin level of
2.92 mg/dL (50 μmol/L) or lower survived for 15 weeks,
on average. In a series of patients treated with TAE and
reported by Leung et al. [24], the mean survival of the
patients with a serum total bilirubin level higher than
2.92 mg/dL (50 μmol/L) was only 34 days, while that of
patients with a serum total bilirubin level lower than 2.92
mg/dL (50 μmol/L) was 165 days. In our study, which
yielded similar results, the mean serum bilirubin level of
the patients who died within 3 weeks was significantly
higher than that of the patients who survived for more
than 1 month (2.20 mg/dL vs. 1.51 mg/dL, p = 0.0052).
Patients with severe ruptures of HCC and poor liver func-
tion have an extremely guarded prognosis and cannot tol-
erate surgical hepatic resection. Therefore, in this study,
TAE was aggressively pursued for the treatment of patients
with ruptured HCC, and the results of a multivariate anal-
ysis revealed that the performance of TAE alone was a sig-
nificant independent factor influencing the overall long-
term survival. The MST in the TAE group was significantly
longer than that in the ConT group. All the patients in the
ConT group died within 35 days as a result of re-rupture,
re-bleeding or hepatic failure. In contrast, the success rate
of TAE was relatively high in our study.
Lau et al. [25] reported that the mean survival period of
patients with ruptured HCC who had been treated with
TAE was 218.3 days for Child-Pugh A patients, 83.4 days
for Child-Pugh B patients, and 11.0 days for Child-Pugh
C patients. However, in their study, the status of HCC pro-
gression was not described in detail. We consider that the
growth of HCC plays an important role in the events lead-
ing up to rupture. In our study, a multivariate analysis
revealed the size of the tumor to be the only independent
factor influencing long-term survival among patients in
whom initial TAE was successfully performed, and both
the survival rate and the MST, as assessed using the Kap-
lan-Meier method, among the patients in whom the max-
imum tumor size was ≤ 7 cm were significantly better than
those among the patients in whom the maximum tumor
size was > 7 cm. Regarding the mechanism of rupture, Zhu
et al. [26] reported that rupture might be initiated by the
invasion and occlusion of the hepatic veins by tumor
cells, resulting in an increase in pressure within the tumor.
Such venous congestion would lead to central tumor
necrosis and trauma, and coagulopathy would lead to
hemorrhage within the tumor. These mechanisms would
further increase the pressure in the HCC tumor, resulting
in the splitting of the overlying liver parenchyma and the
rupture of the HCC into the liver surface. The results
obtained in our study were consistent with this hypothesis
proposed by Zhu et al. In all the patients in our study, the
ruptured HCCs were located on the surface of the liver.
We speculated that the risk of hepatic vein invasion
increases with increasing HCC tumor size. Therefore, the
risk of rupture also increases with increasing tumor size
for tumors located on the surface of the liver. Further-
more, TAE remains unsatisfactory in patients with large
tumors, and further improvements in the prognosis of
patients with large tumors on the surface of their livers
may be difficult to obtain using TAE.
Conclusion
Spontaneous rupture is a serious complication of HCC,
and the 30-day survival in the absence of any treatment is
extremely low. The early mortality rate among patients
with ruptured HCC depends on the immediate treatment
provided. TAE is often feasible and is the treatment of
choice for ruptured HCC. Despite the limitations of this
retrospective study, we preferentially utilized TAE to stop
bleeding in the management of ruptured HCC. Among
cases where initial TAE is successfully performed, the size
of the tumor is a very important factor influencing the sur-
vival of cirrhotic patients with ruptured HCC.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HK and SS performed the literature review, collected the
clinical data, and drafted the manuscript, with contribu-
tions from MY, KF, HM, TU and TH. SK and YN organized
the field survey for data collection. KI, TS, KA, AS, AK, HT,
YA, MI, NK, KK and NU collected the clinical data. SS and
AN were responsible for the design of the study. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported in part by a Grant-in-Aid for research on the 
Third Term Comprehensive Control Research for Cancer from the Minis-
try of Health, Labour and Welfare, Japan to A.N., a grant from the National 
Table 6: Causes of death in both groups
Treatment No. of patients who died Re-rupture or re-bleeding (%) Hepatic failure (%) Others (%)
ConT group 32 23 (72) 9 (28) 0 (0)
TAE group 15 2 (13) 10 (67) 3 (20)
In one of the 16 TAE patients, it was not possible to stop the hemorrhage by use of TAE.
Abbreviations: ConT, conservative treatment: TAE, transcatheter arterial embolizationPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Gastroenterology 2009, 9:29 http://www.biomedcentral.com/1471-230X/9/29
Page 9 of 9
(page number not for citation purposes)
Institute of Biomedical Innovation to A.N., and a grant from the Ministry of 
Education, Culture, Sports, Science and Technology, Japan (KIBAN-B 
20390212) to A.N.
References
1. Xavier Bosch F: Global epidemiology of hepatocellular carci-
noma.  In Liver Cancer Edited by: Okuda K, Tabor E. New York
Churchill Livingstone; 1997:13-28. 
2. Wanebo HJ, Falkson G, Order SE: Cancer of the hepatobiliary
system.  In Cancer Principles and Practice of Oncology 3rd edition.
Edited by: Devita VT Jr, Hellman S, Rosenberg SA. Philadelphia Lippin-
cott; 1989:836-874. 
3. Kobayashi M, Ikeda K, Hosaka T, et al.: Natural history of com-
pensated cirrhosis in the Child-Pugh class A compared
between 490 patients with hepatitis C and 167 with B virus
infections.  J Med Virol 2006, 78:459-465.
4. Okuda K, Fujimoto I, Hanai A, Urano Y: Changing incidence of
hepatocellular carcinoma in Japan.  Cancer Res 1987,
47:4967-4972.
5. Health and Welfare Statistics Association: Health and welfare sta-
tistics.  J Health Welfare Stat 2000, 47:421.
6. Ong GB, Chu EPH, Yu FYK, Lee TC: Spontaneous rupture of
hepatocellular carcinoma.  Br J Surg 1965, 52:123-129.
7. Ong GB, Taw JL: Spontaneous rupture of hepatocellular carci-
noma.  BMJ 1972, 4:146-149.
8. Miyamoto M, Sudo T, Kuyama T: Spontaneous rupture of hepa-
tocellular carcinoma: a review of 172 Japanese cases.  Am J
Gastroenterol 1991, 86:67-71.
9. Vergara V, Muratore A, Bouzari H, et al.: Spontaneous rupture of
hepatocellular carcinoma: surgical resection and long-term
survival.  Eur J Surg Oncol 2000, 26:770-772.
10. Nagasue N, Inokuchi K: Spontaneous and traumatic rupture of
hepatoma.  Br J Surg 1979, 66:248-250.
11. Chearanai O, Plengvanit U, Asavanich C, Damrongsak D, Sindh-
vananda K, Boonyapisit S: Spontaneous rupture of primary
hepatoma: report of 63 cases with particular reference to
the pathogenesis and rationale of treatment by hepatic
artery ligation.  Cancer 1983, 51:1532-1536.
12. Chen MF, Hwang TL, Jeng LB, Jan YY, Wang CS: Surgical treat-
ment for spontaneous rupture of hepatocellular carcinoma.
Surg Gynecol Obstet 1988, 167:99-102.
13. Lai ECS, Wu KM, Choi TK, Fan ST, Wong J: Spontaneous ruptured
hepatocellular carcinoma: an appraisal of surgical treat-
ment.  Ann Surg 1989, 210:24-28.
14. Dewar GA, Griffin SM, Ku KW, Lau WY, Li AKC: Management of
bleeding liver tumours in Hong Kong.  Br J Surg 1991,
78:463-466.
15. Leung KL, Lau WY, Lai PBS, Yiu RYC, Meng MCS, Leow CK: Spon-
taneous rupture of hepatocellular carcinoma. Conservative
management and selective intervention.  Arch Surg 1999,
134:1103-1107.
16. Cherqui D, Panis Y, Rotman N, Fagniez PL: Emergency liver resec-
tion for spontaneous rupture of hepatocellular carcinoma
complicating cirrhosis.  Br J Surg 1993, 80:747-749.
17. Sato Y, Fujiwara K, Furui S, et al.: Benefit of transcatheter arterial
embolization for ruptured hepatocellular carcinoma compli-
cating liver cirrhosis.  Gastroenterology 1985, 89:157-159.
18. Xu HS, Yan JB: Conservative management of spontaneous
ruptured hepatocellular carcinoma.  Am Surg 1994, 60:629-633.
19. Liver Cancer Study Group of Japan: General rules for the clinical
and pathological study of primary liver cancer.  2nd edition.
Tokyo: Kanehara; 2003. 
20. Liu CL, Fan ST, Lo CM, et al.: Management of spontaneous rup-
ture of hepatocellular carcinoma: single-center experience.
J Clin Oncol 2001, 19:3725-3732.
21. Tan FL, Tan YM, Chung AY, Cheow PC, Chow PK, Ooi LL: Factors
affecting early mortality in spontaneous rupture of hepato-
cellular carcinoma.  ANZ J Surg 2006, 76:448-452.
22. Yeh CN, Lee WC, Jeng LB, Chen MF, Yu MC: Spontaneous
tumour rupture and prognosis in patients with hepatocellu-
lar carcinoma.  Br J Surg 2002, 89:1125-1129.
23. Ngan H, Tso WK, Lai CL, Fan ST: The role of hepatic arterial
embolization in the treatment of spontaneous rupture of
hepatocellular carcinoma.  Clin Radiol 1998, 53:338-341.
24. Leung CS, Tang CN, Fung KH, Li MKW: A retrospective review of
transcatheter hepatic arterial embolization for ruptured
hepatocellular carcinoma.  J R Coll Surg Edinb 2002, 47:685-688.
25. Lau KY, Wong TP, Wong WW, Tan LT, Chan JK, Lee AS: Emer-
gency embolization of spontaneous ruptured hepatocellular
carcinoma: correlation between survival and Child-Pugh
classification.  Australas Radiol 2003, 47:231-235.
26. Zhu LX, Wang GS, Fan ST: Spontaneous rupture of hepatocel-
lular carcinoma.  Br J Surg 1996, 83:602-607.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/9/29/pre
pub